BARBARA CARNEMOLLA,LAURA BORSI,LUCIANO ZARDI,DARIO NERI,FREDRIK NILSSON,LORENZO TARLI,CORNELIA HALIN
申请号:
PT06014358
公开号:
PT1719528E
申请日:
2001.02.22
申请国别(地区):
PT
年份:
2012
代理人:
摘要:
Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related macular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions. The antibody may be directed against fibronectin ED-B. The biocidal or cytotoxic molecule may be interleukin-2 (IL-2), doxorubicin, interleukin-12 (IL-12), Interferon-³ (IFN-³), Tumor Necrosis Factor ± (TNF±) or Tissue Factor protein (which may be truncated).